Corebridge Financial’s Coherus Oncology CHRS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-55,061
Closed -$44.4K 546
2025
Q1
$44.4K Sell
55,061
-254
-0.5% -$292 ﹤0.01% 2761
2024
Q4
$76.3K Sell
55,315
-4,176
-7% -$4.68K ﹤0.01% 2683
2024
Q3
$61.9K Buy
59,491
+273
+0.5% +$374 ﹤0.01% 2811
2024
Q2
$102K Buy
+59,218
New +$119K ﹤0.01% 2591

Other funds holding CHRS

Corebridge Financial's CHRS Position: Q2 2025 in Review

Corebridge Financial sold out of Coherus Oncology (CHRS) in Q2 2025, closing a stake of 55,061 shares — an estimated $44.4K sold.

Corebridge Financial first reported a position in CHRS in Q2 2024 and held it in 4 quarters. The position peaked at $102K in Q2 2024. 112 funds tracked by Wall St. Rank hold CHRS as of Q2 2025.

  • Corebridge Financial reported no remaining Coherus Oncology position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 55,061 Coherus Oncology shares in Q2 2025, an estimated $44.4K.
  • Corebridge Financial first reported a position in Coherus Oncology in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Coherus Oncology position peaked at $102K in Q2 2024.
  • 112 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.